Form D · Biotechnology
MycoMedica Life Sciences, PBC
Shelton, WA · CIK 0001875901
Offering snapshot reported Dec 28, 2021 · SEC filing
- Reported sold
- $22.5M Offering amount: $22.5M
- Investors reported
- 73 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 25, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 28, 2021 | Initial | $22,495,180 | No comparison | 73 | SEC filing |
| Dec 28, 2021 | Initial | $7,389,366 | No comparison | 81 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-426887
Does not include $3,432,727.10 sold to 30 investors who reside outside the United States
Source: Form D, filed Dec 28, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tad Buchanan | Director, Executive |
| James Joaquin | Director |
| Pamela Kryskow | Director |
| John Parrish | Executive |
| Paul Stamets | Director, Executive, Promoter |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
50 Se Nelson Road
Shelton, WA, 98584
Shelton, WA, 98584